Global leader in assay technologies releases new kits featuring “All-in-One-Well” functionality for investigation of disease-related cellular events

DENVER–Today at the 100th Annual Meeting of the American Association for Cancer Research in Denver, PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, unveiled a new series of AlphaScreen® SureFire® assay kits for analysis of cellular signaling pathways.

The six new assays bring the AlphaScreen® SureFire® portfolio to a total of 57 kits. AlphaScreen® SureFire® kits feature assays for mapping of cellular kinase pathways involved in several complex diseases, including cancer, diabetes, inflammation and Alzheimer’s disease.

“The AlphaScreen® SureFire® platform continues to be an innovative, homogeneous, flexible and sensitive approach that helps with better screening for potential new drugs. It provides researchers with more in-depth knowledge of where potential lead compounds ‘hit’ against their cellular targets,” said Richard M. Eglen, Ph.D., president, Bio-discovery, PerkinElmer. “Researchers can benefit from the ability to engage multiple assay options, enabling interrogation of various signaling pathways, receptors and kinase targets, as well as measure full-length, endogenous protein phosphorylation in a cell-based format, with high sensitivity and precision.”

PerkinElmer’s AlphaScreen® SureFire® platform is a highly sensitive tool for measuring cellular protein phosphorylation. AlphaScreen® SureFire® assays provide a cell-based environment for allowing the measurement of endogenous proteins in cell lysates, as well as measurement of key signal transduction pathways implicated in many disease states. AlphaScreen® SureFire® kits greatly simplify complex protocols, facilitating their automation for high-throughput screening, and help researchers transition from time consuming Western Blot or ELISA methods. Using AlphaScreen® SureFire® kits, it is now possible to culture cells and detect key analytes using an “All-in-One-Well” format. A range of complex biological fluids can be assayed without the need for arduous separation and wash steps. Alternatively, cells from one well can be used in multiple assays analyzing pathways or allowing for kinase profiling.

The newest AlphaScreen® SureFire® kits include assays for the study of cellular signaling pathways involved in cancer and inflammation:

AKT Signaling Pathway

Total Akt1

Total Akt 1/2

Phospho-Akt 1/2/3 (Thr308)

Phospho-Akt 1/2/3 (Ser473)

TGFâ/Smad Signaling Pathway

Phospho-Smad3 (Ser423/425)

Receptor Signaling

Phospho-VEGF2 Receptor (Tyr1175)

Please visit www.perkinelmer.com/surefire to view the full product listing.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2 billion in 2008, has about 8,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

SureFire® is a registered trademark of TGR BioSciences Pty Ltd.